

**Declaration of Conformity of the Management Board and the Supervisory Board of BioNTech SE
with the German Corporate Governance Code (“Code”) pursuant to Section 161 of the German
Stock Corporation Act (*AktG*).**

The Management Board and Supervisory Board have dealt in detail with the recommendations of the Corporate Governance Code (“Code”) and on 27 February 2025 adopted the following Declaration of Conformity pursuant to Section 161 (1) of the German Stock Corporation Act (*AktG*):

With the exception of the points listed below, BioNTech SE (“Company”) has complied with all recommendations of the Code in the version from 28 April 2022 and will continue to comply with them in the future.

- According to Item B.3 of the Code, the initial appointment of Management Board members shall be for a period of no more than three years. In deviation from this, the Management Board member Annemarie Hanekamp was appointed with effect from 1 July 2024 for a period of four years. With regard to Ms. Hanekamp's many years of experience and individual qualifications, the Company considers an initial appointment of four years to be necessary and appropriate. Furthermore, the Supervisory Board considered the initial appointment for a period of four years to be in the best interest of the Company in order to be able to implement long-term strategic corporate goals and decisions, particularly in the commercial area.
- According to Item C.7 of the Code, it is recommended that more than half of the members of the Supervisory Board be independent of the Company and the Management Board. Accordingly, a Supervisory Board member is independent of the Company and its Management Board if he or she has no personal or business relationship with the Company or its Management Board that could constitute a material and not merely temporary conflict of interest. In assessing independence, the length of service on the Supervisory Board shall be taken into account, among other factors. Despite the fact that two out of six members of the Supervisory Board have been on the Supervisory Board for longer than the twelve years recommended by the Code, all members of the Supervisory Board are considered to be independent. The Supervisory Board considers it advantageous and essential for the Company to maintain the knowledge and experience currently available on the Board. This includes many years of knowledge of the Company and its industry as well as comprehensive professional knowledge in the areas of finance, economics, science and capital markets, which is particularly important in view of the current, steady global growth and change of the Company. Due to the long-standing relationship with the Company and the existing economic independence from the Company, as well as the absence of other concerns that could cause possible conflicts of interest, the length of membership of the two Supervisory Board members Mr. Helmut Jeggle and Mr. Michael Motschmann does not conflict with their respective independence (see Item C.8 of the Code).

Mainz, 27 February 2025

BioNTech SE

Management Board

Prof. Dr. Ugur Sahin
Chief Executive Officer, CEO

Jens Holstein
Chief Financial Officer, CFO

Supervisory Board

Helmut Juggle
Chairman of the Supervisory Board